# University of New Haven

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/university-of-new-haven/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 75.5 |
| Citations | 505,204 |
| City | West Haven |
| Country | US |
| Description | University of New Haven is a research organisation in West Haven, US. OpenAlex records 10,192 works and 505,204 citations for it. 2,594 researchers list it as their most recent affiliation. |
| Homepage | https://www.newhaven.edu |
| OpenAlex ID | https://openalex.org/I40253897 |
| Researchers | 2,594 |
| ROR ID | https://ror.org/00zm4rq24 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q917899 |
| Works | 10,192 |

## University papers

Showing 12 of 25.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2021/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-1-2020/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Non–Small Cell Lung Cancer, Version 4.2024](https://scholariq.org/papers/non-small-cell-lung-cancer-version-4-2024/)
- [Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer](https://scholariq.org/papers/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of/)
- [Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study](https://scholariq.org/papers/five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell/)

## University top topics

Showing 8 of 23.

- [Forensic and Genetic Research](https://scholariq.org/topics/forensic-and-genetic-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Child and Adolescent Psychosocial and Emotional Development](https://scholariq.org/topics/child-and-adolescent-psychosocial-and-emotional-development/)
- [Psychotherapy Techniques and Applications](https://scholariq.org/topics/psychotherapy-techniques-and-applications/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Advanced Malware Detection Techniques](https://scholariq.org/topics/advanced-malware-detection-techniques/)
- [Digital and Cyber Forensics](https://scholariq.org/topics/digital-and-cyber-forensics/)
- [Crime Patterns and Interventions](https://scholariq.org/topics/crime-patterns-and-interventions/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.